Leerink Partnrs Has Bearish Outlook for SAGE FY2025 Earnings

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Investment analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of ($3.05) for the year, down from their prior estimate of ($2.95). The consensus estimate for Sage Therapeutics' current full-year earnings is ($6.46) per share. Leerink Partnrs also issued estimates for Sage Therapeutics' FY2026 earnings at ($1.30) EPS, FY2027 earnings at ($1.64) EPS and FY2028 earnings at ($1.40) EPS.

A number of other brokerages also recently commented on SAGE. HC Wainwright reiterated a "neutral" rating and set a $14.00 target price on shares of Sage Therapeutics in a research note on Wednesday, November 20th. Oppenheimer cut their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Wednesday, October 30th. Scotiabank decreased their price objective on Sage Therapeutics from $17.00 to $14.00 and set a "sector outperform" rating for the company in a research report on Wednesday, October 30th. Needham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a report on Wednesday, November 20th. Finally, Royal Bank of Canada upgraded shares of Sage Therapeutics from an "underperform" rating to a "sector perform" rating and set a $4.00 price target for the company in a research report on Thursday, November 21st. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $10.53.

Sage Therapeutics Stock Down 0.5 %

NASDAQ SAGE traded down $0.04 during trading on Friday, hitting $7.23. The stock had a trading volume of 1,379,322 shares, compared to its average volume of 2,664,109. The company has a market capitalization of $441.95 million, a PE ratio of -1.29 and a beta of 0.94. The firm has a 50 day moving average price of $6.11 and a 200 day moving average price of $7.12. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $27.39.

Institutional Trading of Sage Therapeutics

Institutional investors have recently made changes to their positions in the stock. RTW Investments LP boosted its stake in shares of Sage Therapeutics by 2.0% during the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company's stock valued at $40,372,000 after buying an additional 111,123 shares during the period. State Street Corp grew its stake in Sage Therapeutics by 18.2% in the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company's stock valued at $21,127,000 after purchasing an additional 451,377 shares in the last quarter. Geode Capital Management LLC increased its position in Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock worth $8,975,000 after purchasing an additional 3,757 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Sage Therapeutics by 10.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company's stock worth $3,265,000 after purchasing an additional 43,617 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Sage Therapeutics by 11.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 186,039 shares of the biopharmaceutical company's stock valued at $1,343,000 after buying an additional 18,814 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.